Physician profile
Guy A Francis
NPI 1376554378
$10,181.65
in general payments reported to CMS, 2019-2025
33 companies · $2,274 in 2025
The $2,274 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $922 · 2021: $1,175 · 2022: $875 · 2023: $1,584 · 2024: $2,323 · 2025: $2,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,002 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,001.91 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,150.79 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $2,177.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $722.34 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $557.83 | 2022-2025 | Freestyle Libre |
| Astellas Pharma US INC | $422.18 | 2019-2025 | Veozah, Myrbetriq |
| Arbor Pharmaceuticals, INC. | $372.65 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $367.37 | 2022-2025 | Zoryve, Seglentis, Livalo |
| Abbvie INC. | $308.28 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $261.06 | 2023-2025 | Horizant, Edarbyclor, Edarbi |
| Pfizer INC. | $254.23 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $217.63 | 2019-2022 | |
| Exact Sciences Corporation | $194.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $144.00 | 2024-2025 | Auvelity |
| Biotronik INC. | $138.99 | 2025 | Acticor 7 Vr-T Dx |
| Merck Sharp & Dohme LLC | $133.94 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $132.50 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $123.17 | 2025 | |
| Dexcom, INC. | $120.26 | 2021-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.32 | 2020-2021 | |
| Allergan, INC. | $65.42 | 2020 | |
| Xeris Pharmaceuticals, INC. | $30.91 | 2024-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2019-2024 | Xifaxan |
| Genentech USA, INC. | $28.73 | 2021-2022 | |
| Boston Scientific Corporation | $17.12 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.51 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $16.01 | 2021 | |
| Alk-Abello, INC | $15.99 | 2025 | Neffy |
| Janssen Pharmaceuticals, INC | $14.74 | 2019 | |
| Cashflow Solutions, LLC | $14.63 | 2022 | |
| Glaxosmithkline, LLC. | $14.55 | 2021 | |
| Gilead Sciences, INC. | $14.48 | 2019 | |
| Global Blood Therapeutics, INC. | $14.29 | 2022 | |
| Sobi, INC | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.